N onalcoholic fatty liver disease (NAFLD), the hepatic manifestation of the metabolic syndrome, is the most common chronic liver disease in the United States, affecting up to 100 million Americans. 1 NAFLD encompasses a spectrum of disease, including simple steatosis, nonalcoholic steatohepatitis (NASH), and NASH-related cirrhosis. More than one-third of children and adults in the United States are obese and more than 20 million Americans have diabetes, resulting in a large at-risk population for NAFLD.
2 Approximately 2%-5% of patients with NAFLD progress to NASH, among whom a subset will develop cirrhosis and cirrhosis-related complications including hepatocellular carcinoma (HCC). 3 Prior studies have suggested Hispanics may have disproportionately higher and black persons may have lower NAFLD prevalence and severity compared with non-Hispanic white persons. 4, 5 Additionally, NAFLD is increasingly being recognized in Asian patients, even at "normal" body mass index values. 6 However, the magnitude of these disparities is currently poorly characterized, because prior studies have been underpowered. Furthermore, most studies evaluated NAFLD prevalence, severity, or prognosis, with no studies evaluating disparities across the entire NAFLD spectrum. Racial/ethnic disparities in NAFLD prevalence and severity can be multifactorial, driven not only by genetic and environmental factors but also socioeconomic status and differential access to health care. Furthermore, these influences may differ in significance along the NAFLD spectrum, with some influences playing a central role in NAFLD development and others being more important for disease progression or NAFLD prognosis. Having a better understanding of what disparities exist and their magnitude is the first step to identifying contributing factors and reducing disparities through targeted interventions. Thus, the aim of this meta-analysis was to characterize racial/ethnic disparities in NAFLD prevalence, disease severity, and prognosis among patients in the United States.
Methods

Literature Search Strategy
We searched Ovid MEDLINE, Ovid MEDLINE InProcess, Ovid EMBASE, and the Cochrane Library from inception to August 2, 2016, using search terms described in the Supplementary Methods. A manual search of references from relevant articles was performed to identify publications missed by search terms. A manual search of American Association for the Study of Liver Diseases, European Association for the Study of the Liver, Digestive Diseases Week, and American College of Gastroenterology meeting abstracts from 2014 to 2016 was performed. The study was conducted in accordance with Preferred Reporting Items for Systematic Review and Meta-analysis guidelines. 7 
Eligibility Criteria
Included studies met the following criteria: (1) cohort, cross-sectional, or case-control trials including original data characterizing NAFLD-related racial/ethnic disparities among adult patients in the United States; (2) NAFLD diagnosed using biochemical, radiologic, or histologic criteria per American Association for the Study of Liver Disease guidelines; and (3) reported at least 1 of NAFLD prevalence, severity, or prognosis. We excluded studies that (1) did not stratify NAFLD prevalence, severity, or prognosis by race/ethnicity; (2) had insufficient data to determine necessary denominator for prevalence or severity; or (3) included patients with other causes of hepatic steatosis (eg, alcoholic liver disease, medication-induced, or HIV infection). Additional exclusion criteria included (1) lack of original data (eg, commentaries, review articles), (2) nonhuman studies, (3) incomplete data, and (4) non-English language. For studies with overlapping cohorts, articles with the most contemporary cohort or complete data were selected.
Study Selection and Data Extraction
Studies were screened and reviewed in a collaborative, multistep process. After removing duplicates, 2 investigators (N.E.R. and S.O.) independently reviewed publications identified by the search strategy. Articles were screened based on title and abstract for relevance, followed by full text review to assess for inclusion. Disagreements between authors were resolved by discussion with a third reviewer (A.G.S.). Using standardized forms, 2 authors (N.E.R. and S.O.) independently extracted data including patient demographics (including race/ ethnicity), method of NAFLD diagnosis, NAFLD prevalence, NAFLD severity, and NAFLD prognosis outcomes (including liver-related and all-cause mortality). Study quality was assessed using a modified checklist based on the National Institutes of Health Quality Assessment Tool for Observational Cohort and Cross-sectional Studies, which rates observational studies on a 14-point scale based on study sample appropriateness, comparability of study groups, and adequacy of assessing exposure and outcomes.
Data Synthesis and Statistical Analysis
For each study, a risk ratio for each study outcome of interest was calculated according to race/ethnicity (white vs black, and white vs Hispanic). Data for other racial/ethnic groups (eg, Asians) were limited by small sample sizes and not included in analyses. We first evaluated NAFLD prevalence in population-based and high-risk cohorts. Cohorts were deemed high-risk if they predominantly included patients with obesity (eg, patients undergoing bariatric surgery), diabetes, or history of chronic liver disease. We next evaluated NAFLD severity, as assessed by 2 measures: presence of NASH, the progressive form of NAFLD that can lead to cirrhosis and cirrhosis-related complications; and presence of advanced (stage F3-F4) fibrosis. Although some studies reported components of NAFLD Activity Score (NAS) including degree of inflammation and steatosis, an insufficient number reported racial/ethnic differences in composite NAS to include as a severity measure. Finally, we evaluated NAFLD prognosis, including liver-related and all-cause mortality. Association between NAFLD and cardiovascular outcomes has been described elsewhere and not evaluated in this study. 8 For each study outcome of interest, point estimates and 95% confidence intervals (CIs) were calculated using the adjusted Wald method. We calculated pooled risk ratio estimates for NAFLD prevalence and severity using the DerSimonian and Laird method for a random effects model. Heterogeneity was evaluated graphically by examining forest plots and statistically using the inconsistency index (I 2 statistic). I 2 values >75% are consistent with high heterogeneity, and values between 50% and 75% are considered moderate heterogeneity. When there were concerns for heterogeneity, sensitivity analyses, in which 1 study was removed at a time, were performed to evaluate for undue influence of a single study. Publication bias was evaluated graphically by funnel plot analysis and statistically using Egger test. An asymmetric funnel plot suggests possibility of small studies not being published. All data analysis was performed using Stata version 14.2 (StataCorp, College Station, TX).
Results
Literature Search
The search strategy yielded 7921 potentially relevant citations. After removing 1893 duplicate citations there were 6028 unique citations. After initial review, 2428 titles met inclusion criteria, and abstracts were reviewed. Of 351 publications that underwent full text review, 46 met inclusion criteria. Fourteen studies contained overlapping data from National Health and Nutrition Examination Survey, so we selected the most inclusive studies representing patients from nonoverlapping National Health and Nutrition Examination Survey cohorts (n ¼ 2). 9, 10 We also excluded an additional study only reporting prevalence for racial/ethnic minority patients but not white persons, because risk ratios comparing minority populations with the index white population could not be calculated. 11 Searches of meeting abstracts yielded 3 abstracts with sufficient data for inclusion, and recursive literature searches revealed 1 additional article meeting inclusion criteria, for a total of 34 studies. Agreement between reviewers for final study inclusion exceeded 90%. Supplementary Figure 1 represents a flow diagram depicting study selection.
Study Characteristics
We identified 34 studies, with a total of 368,569 patients, characterizing racial/ethnic disparities in NAFLD prevalence, severity, or prognosis. Studies had racial/ethnic diversity including 216,501 (58.7%) white persons, 57,412 (15.6%) black persons, 43,737 (11.9%) Hispanics, 10,100 (2.7%) Asians, and 40,819 (11.1%) "other" race/ethnicity. All included studies reported races/ethnicities as mutually exclusive categories. Of included studies, 17 (n ¼ 350,076) characterized disparities in NAFLD prevalence, 18 (n ¼ 16,083) in NAFLD severity, and 6 (n ¼ 15,187) reported disparities in NAFLD prognosis; 7 studies reported disparities in more than 1 study outcome. Six studies focused on white-black disparities and did not include data for Hispanics, whereas 1 study focused on white-Hispanic disparities and did not include data for black persons. [12] [13] [14] [15] [16] [17] [18] Of NAFLD prevalence studies, 9 were conducted among population-based cohorts and 8 were conducted in highrisk cohorts. Of NAFLD severity studies, 10 evaluated presence of NASH and 11 characterized fibrosis staging. There were fewer studies of NAFLD prognosis including 2 full publications and 4 meeting abstracts, and reporting of outcomes was not standardized among available studies. We found no evidence of publication bias for NAFLD prevalence or severity by Egger test (P > .05 for each) or funnel plot inspection.
Nonalcoholic Fatty Liver Disease Prevalence in Population-Based Cohorts
Nine studies (n ¼ 343,393) assessed NAFLD prevalence in population-based cohorts (Table 1) . 9, 10, 12, 13, 16, [19] [20] [21] [22] NAFLD diagnosis was determined by presence of steatosis on ultrasound (n ¼ 3), steatosis per magnetic resonance (MR) spectroscopy (n ¼ 2), steatosis on computed tomography (n ¼ 2), elevated aminotransferases alone (n ¼ 1), and International Classification of Diseases (ICD)-9 codes (n ¼ 1). Four studies required exclusion of other liver diseases to make a NAFLD diagnosis; however, only 1 required histologic confirmation. 22 NAFLD prevalence ranged widely from 6.6% to 46.0% between studies, with a pooled prevalence of 11.2% (95% CI, 11.1%-11.3%). Compared with white persons, Hispanics had higher risk of NAFLD with a pooled relative risk (RR) of 1.36 (95% CI, 1.08-1.73), and black persons had lower risk of NAFLD with a pooled RR of 0.68 (95% CI, 0.54-0.84). There was significant heterogeneity (I 2 >90%) in both comparisons; on visual inspection of forest plots, the study by Reddy et al 20 was an outlier. This study was conducted among hospitalized patients and NAFLD diagnosis was based on ICD-9 codes, which have low accuracy, so it was excluded in sensitivity analyses. After removing this study, pooled NAFLD prevalence was 15.1% (95% CI, 14.8%-15.5%). NAFLD prevalence was highest in Hispanics (22.9%; 95% CI, 21.6%-24.1%), intermediate in white persons (14.4%; 95% CI, 14.0%-14.8%), and lowest in black persons (13.0%; 95% CI, 12.2%-13.9%). Compared with white persons, the pooled RR of NAFLD in Hispanics was 1.47 (95% CI, 1.35-1.61), and I 2 decreased to 41% ( Figure 1A) ; the pooled RR of NAFLD in black persons compared with white persons was 0.74 (95% CI, 0.69-0.80), and I 2 decreased to 0% ( Figure 1B ).
Nonalcoholic Fatty Liver Disease Prevalence in High-Risk Cohorts
Eight studies (n ¼ 6683) assessed NAFLD prevalence in high-risk cohorts (Table 1) .
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Black persons had lower risk of NAFLD than white persons in high-risk patients, with a pooled RR of 0.85 (95% CI, 0.75-0.97). There was moderate heterogeneity (I 2 >50%) and studies by Bril 23 and Setiawan 26 were outliers on visual inspection of forest plots. Both studies used noninvasive means to define NAFLD (MR spectroscopy and ICD-9 codes, respectively), whereas remaining studies used liver biopsy. On sensitivity analysis removing all 3 studies defining NAFLD noninvasively, the pooled RR was 0.78 (95% CI, 0.67-0.91), and I 2 decreased to 47% ( Figure 1B ).
Nonalcoholic Fatty Liver Disease Severity
Eighteen studies (n ¼ 16,083) addressed racial/ethnic differences in NAFLD severity (Table 2) (Figure 2A) . The pooled RR of NASH in black persons compared with white persons was 0.72 (95% CI, 0.60-0.87), with minimal heterogeneity (I 2 <20%) ( Figure 2B 
Nonalcoholic Fatty Liver Disease Prognosis
Six studies assessed racial/ethnic differences in prognosis among NAFLD patients (Table 3) . 30, [39] [40] [41] [42] [43] All studies were retrospective and outcomes included progression to cirrhosis, development of HCC, liver-related mortality, and all-cause mortality. Heterogeneity of outcomes precluded pooling of data. One study reported Hispanics had higher odds of developing cirrhosis (odds ratio, 2.7; 95% CI, 1.2-5.8) and HCC (odds ratio, 2.5; 95% CI, 1.1-5.5) compared with white persons, although another study found no significant difference in cirrhosis proportions between Hispanics and white persons (6.7% vs 5.6%; P ¼ .65). Studies on liver-related and all-cause mortality also reported discordant results. Younossi et al 43 reported significantly higher hazards of all-cause mortality among black persons than white persons (hazard ratio, 1.36; 95% CI, 1.03-1.78) and lower hazards among other racial/ ethnic minorities including Hispanics compared with white persons (hazard ratio, 0.65; 95% CI, 0.43-0.96). In contrast, another study reported nonsignificant higher hazards of liver-related and all-cause mortality among white persons than racial/ethnic minorities and another reported no differences in all-cause mortality between racial/ethnic groups.
Quality Assessment
Quality assessment of studies is provided in Table 4 . Four studies had quality scores <5, 17 had a score of 5-7, and 13 studies had quality scores >7. Three of the 4 studies with quality scores <5 were abstracts. Most studies had appropriate cohort selection, including representativeness of the at-risk cohort. The most common limitation observed was cross-sectional study design (27 of 34 studies), which precluded the exposure being measured before outcome, sufficient time frame, repeated measurements of the exposure over time, and loss to follow-up reporting. Although outcomes were clearly defined and valid in most studies, ascertainment method for those outcomes varied. Some studies used imaging including ultrasound, computed tomography, or MR imaging for NAFLD prevalence, whereas others used liver enzymes, which have lower sensitivity for NAFLD ascertainment. Similarly, most studies assessed NAFLD severity via histology, although some studies used less reliable methods, such as imaging and/or liver enzymes. Finally, several studies used large administrative databases (eg, National Health and Nutrition Examination Survey), which have inherent limitations, including missing or incomplete data on diagnosis of NAFLD, thus increasing risk of ascertainment bias.
Discussion
Although NAFLD prevalence varied widely among studies, particularly in population-based cohorts, our systematic review highlights NAFLD is very common in the United States. We found nearly 1 in 6 of all Americans and 1 in 2 high-risk individuals have NAFLD. NAFLD prevalence seemed highest among Hispanics and lowest among black persons, although differences were less marked in high-risk cohorts than population-based cohorts. Among patients with NAFLD, risk of NASH is greatest in Hispanics and lowest in black persons; however, the proportion with advanced fibrosis did not significantly differ between racial/ethnic groups. Data are discordant regarding the presence of racial/ethnic disparities in NAFLD-related prognosis, such as progression to cirrhosis and/or mortality. To the best of our knowledge, this is the first systematic review to quantify racial/ethnic differences in NAFLD prevalence, severity, and prognosis. These data provide insight into where in the NAFLD-to-NASH cirrhosis continuum disparities start to arise and suggest determinants of each step may differ.
Our findings reflect the wide variation in NAFLD prevalence among studies, particularly in populationbased cohorts, ranging from 6.6% to 46.0%. Prevalence seemed to depend on method of NAFLD diagnosis, with highest prevalence reported in studies using ultrasound or MR spectroscopy. As expected, NAFLD prevalence was higher in high-risk cohorts than population-based cohorts, with approximately 50% of patients with obesity or diabetes having NAFLD, independent of race/ ethnicity. Despite variation in reported prevalences, observed racial/ethnic disparities were fairly consistent across studies. The highest NAFLD burden was evident among Hispanics, the fastest growing demographic in the United States. Population-based studies suggest nearly 1 in 4 Hispanics have NAFLD compared with only approximately 1 in 10 blacks. However, differences in prevalence were less marked in high-risk cohorts, suggesting differences in prevalence may be, in part, driven by the differential distribution of underlying risk factors including obesity and diabetes. These data are important to consider when determining targets for NAFLD screening in the general population and for determining pretest likelihood of NAFLD in the differential diagnosis for patients with aminotransferase elevations. Development and validation of accurate predictive models, including such factors as age, race/ethnicity, and metabolic syndrome features, may help target NAFLD screening to those at highest risk. Among patients with NAFLD, nearly 30% had evidence of NASH and nearly 20% had evidence of advanced fibrosis (stage F3-F4), underscoring the high potential for NAFLD-related morbidity and need for effective treatment strategies. Currently, lifestyle modifications remain the cornerstone of NASH therapy and although there are no currently widely available pharmacologic therapies, several novel drugs are in development. Given the widespread burden of NAFLD in the United States, it may not be feasible to identify all at-risk persons. It may be more cost-effective to concentrate efforts on identifying patients who are most likely to develop adverse consequences of NASH (including cirrhosis, portal hypertensive complications, and HCC) and those who would derive most benefit from early preventative and therapeutic interventions. These patients would also need to be closely monitored for development of cirrhosis, at which time such measures as HCC surveillance and varices screening should be implemented.
It is unclear from current literature if NAFLDrelated severity and prognosis differs between racial/ ethnic groups. Although Hispanic NAFLD patients were more likely to have NASH than their counterparts, presence of advanced fibrosis did not differ between racial/ethnic groups and data characterizing prognosis were discordant. These data highlight the need for further research in areas of NASH severity and prognosis, because current data are sparse and inconsistently reported.
Although several studies have described racial/ ethnic and socioeconomic disparities, further studies are needed to characterize precisely why these disparities exist. Although NAFLD disease burden is related to metabolic syndrome components, such as obesity, diabetes, and dyslipidemia, NAFLD risk extends beyond environmental factors. For example, diabetes and obesity are both more common among black persons compared with white persons; however, the latter group has significantly higher risk of NAFLD. 2, 44 Cultural and socioeconomic factors are also likely implicated including dietary and exercise habits, access to health care, and allostatic load experienced by those living in poverty. Prior studies have demonstrated genetic risk factors play a large role in NAFLD. In particular, single nucleotide polymorphisms in PNPLA3, TM6SF2, and MBOAT have unequal distributions across races/ethnicities, which contributes to the observed differences in NAFLD prevalence. [45] [46] [47] For instance, the I148M variant in PNPLA3 is strongly associated with hepatic fat content, and occurs most frequently in Hispanics (49%) compared with non-Hispanic white persons (23%) and black persons (17%). 45 Additionally, recent studies have demonstrated polymorphisms in PNPLA3 are frequent in Asian Indians with NAFLD, which is likely contributing to the increasing prevalence of NAFLD in this population. 48 Although genetic factors are clearly implicated, further studies are needed to characterize the relative contribution of genetic and environmental factors toward NAFLD pathogenesis to help inform risk stratification and future prevention efforts. Additionally, it is possible mechanisms for NAFLD progression differ from mechanisms that lead to development of NAFLD. Our study supports this hypothesis, because racial/ethnic disparities are less apparent for NAFLD severity and prognosis than prevalence, although the paucity of data on disparities in NAFLD prognosis should be noted. Although some genetic factors, such as polymorphisms in PNPLA3, are also associated with NAFLD severity and prognosis, 49 it is unclear if this is true for other genetic factors, such as TM6SF2 or environmental factors.
Studies in our meta-analysis have several inherent limitations given the complexity of racial/ethnic health disparities. First, data on race and ethnicity are selfreported and may not be collected reliably. Second, differences between racial groups may be difficult to interpret, because there may be as much genetic heterogeneity within races as between races. One particular challenge becoming more common over time is the classification of multiethnic individuals, who are often forced into a single category. Finally, race and socioeconomic status are often highly correlated, complicating interpretation of observed disparities in health outcomes. Racial/ethnic differences in some health outcomes can be mitigated, or even disappear, if adequately adjusting for socioeconomic status; however, this can often be difficult, particularly for retrospective analyses.
Additional limitations of the NAFLD-related literature are worth acknowledging. First, most included studies in our analysis were cross-sectional with limitations in study quality. There was also heterogeneity in method of NAFLD diagnosis; some studies used liver histology or MR spectroscopy, whereas others used ICD-9 codes and laboratory tests, which may underestimate or overestimate NAFLD prevalence. Additionally, although the NAS is the most accepted measure of NASH severity, racial/ethnic differences in NAS scores were rarely reported. Finally, there were little data on other underrepresented minority groups, such as Asian/Pacific Islanders and Native Americans.
While awaiting effective NAFLD chemoprevention and treatment, our meta-analysis provides important data characterizing NAFLD disparities. Our study highlights NAFLD is common in the United States, with nearly 1 in 6 of all Americans and 1 in 2 high-risk individuals having NAFLD. There are notable racial and ethnic disparities in NAFLD prevalence and severity, with the highest burden in Hispanics and lowest in black persons. Few studies have evaluated racial/ethnic differences in NAFLD prognosis, with discordant results, demonstrating the need for further research in this area. Studies are also needed to identify determinants of NAFLD disparities, which would be the first crucial step to identify appropriate intervention targets to reduce racial/ethnic disparities and improve NAFLD morbidity and mortality.
